Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 21, 2026

'It's that simple': Kevin O'Leary says this one number can turn your $65K salary into millions — will it work for you?

View original at finance.yahoo.com
'It's that simple': Kevin O'Leary says this one number can turn your $65K salary into millions — will it work for you? CHANDAN KHANNA/Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Everyone should invest 15% of every income source — paycheck, gifts, or side hustle earnings — to accelerate wealth building

    60% confidence

  • Historical stock market returns are 8% to 10% annually, enabling exponential wealth growth for consistent investors

    60% confidence

  • The S&P 500 delivered annualized returns of 13.51% in the 10 years leading up to February 2026

    60% confidence

  • Nearly 50% of Americans are making one big Social Security mistake

    60% confidence

  • Saving before spending is the non-negotiable foundation of wealth building

    60% confidence

  • Gold will reach $6,000 per ounce before the end of 2027

    60% confidence

  • Saving, investing, and compounding is a simple formula to build wealth from any salary level

    60% confidence

  • Low-cost index funds outperform most amateur and professionally managed money

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com